Genmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 94.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,620 shares of the company’s stock after selling 30,383 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Genmab A/S were worth $33,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GMAB. GAMMA Investing LLC lifted its stake in Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock worth $656,000 after purchasing an additional 31,343 shares during the last quarter. Park Avenue Securities LLC bought a new position in Genmab A/S during the first quarter worth $276,000. Fifth Third Bancorp lifted its stake in Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company’s stock worth $825,000 after purchasing an additional 6,015 shares during the last quarter. QRG Capital Management Inc. lifted its stake in Genmab A/S by 213.7% during the first quarter. QRG Capital Management Inc. now owns 74,847 shares of the company’s stock worth $1,465,000 after purchasing an additional 50,990 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in Genmab A/S by 169.9% during the first quarter. Blue Trust Inc. now owns 7,413 shares of the company’s stock worth $145,000 after purchasing an additional 4,666 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

GMAB stock opened at $31.81 on Monday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $33.63. The stock’s fifty day moving average is $26.86 and its two-hundred day moving average is $22.91. The stock has a market capitalization of $20.42 billion, a price-to-earnings ratio of 15.98, a PEG ratio of 1.79 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Wall Street Zen upgraded Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. HC Wainwright raised their target price on Genmab A/S from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a research note on Tuesday, September 23rd. Finally, Zacks Research upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.80.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.